Announcements
- Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
- Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
- Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
- Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
More ▼
Key statistics
On Tuesday, Xenon Pharmaceuticals Inc (XP0:DUS) closed at 39.80, -14.22% below its 52-week high of 46.40, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.80 |
---|---|
High | 39.80 |
Low | 39.60 |
Bid | 40.00 |
Offer | 40.60 |
Previous close | 40.20 |
Average volume | 5.11 |
---|---|
Shares outstanding | 75.46m |
Free float | 74.08m |
P/E (TTM) | -- |
Market cap | 3.26bn USD |
EPS (TTM) | -2.73 USD |
Data delayed at least 15 minutes, as of May 07 2024 18:30 BST.
More ▼